Skip to Main Content

Moderna is moving at unprecedented speed to develop a vaccine to prevent infection from the novel coronavirus. But the biotech’s soaring stock price is moving faster, which raises an important question: Are investors taking on too much risk?

Since late February, Moderna shares have more than tripled in value — making it one of the top-performing biotech stocks this year. On Monday, shares hit an all-time high of $66.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.